Angle (AGL)

Sector:

Support

Index:

FTSE AIM All-Share

0.000p
   
  • Closing Price Chg:
      1.00p
  • 52 Week High: 19.00p
  • 52 Week Low: 7.00p
  • Currency: UK Pounds
  • Shares Issued: 322.64m
  • Volume: 0
  • RiskGrade: 312

Angle Overview

ANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE’s proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -995.4% -515.1%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 14.8 11.1
Pr/Book 1.4  
Latest F'cast
Revenue 110.0% 32.7%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Angle Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 0.58 (9.04) (4.61)p n/a n/a n/a n/a 0.0%
31-Dec-20 0.76 (13.74) (6.51)p n/a n/a n/a n/a 0.0%
31-Dec-21 1.01 (17.36) (6.66)p n/a n/a n/a n/a 0.0%
31-Dec-22 1.04 (24.44) (8.96)p n/a n/a n/a n/a 0.0%
31-Dec-23 2.19 (21.63) (7.72)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Angle Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 2.90 (14.94) (4.81)p n/a n/a n/a n/a 0.0%
31-Dec-25 4.30 (13.02) (3.89)p n/a n/a n/a n/a 0.0%
31-Dec-26 7.30 (10.00) (3.13)p n/a n/a n/a n/a 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

Angle Company Announcements

Notice of Results 23-May-2025 07:00 RNS
Issue of LTIP Options and Share Options 21-Mar-2025 07:00 RNS
Results of Eisai Phase 2 pilot study 21-Mar-2025 07:00 RNS

Latest Angle Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Angle Market Data

Currency UK Pounds
Share Price 10.00p
Closing Price Change 1.00p
% Change 0.00 %
52 Week High 19.00p
52 Week Low 7.00p
Volume 0
Shares Issued 322.64m
RiskGrade 312

Angle Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
34.99% below the market average34.99% below the market average34.99% below the market average34.99% below the market average34.99% below the market average
8.89% above the sector average8.89% above the sector average8.89% above the sector average8.89% above the sector average8.89% above the sector average
Price Trend
57.99% below the market average57.99% below the market average57.99% below the market average57.99% below the market average57.99% below the market average
56.7% below the sector average56.7% below the sector average56.7% below the sector average56.7% below the sector average56.7% below the sector average
Income Not Available
Growth
55.19% above the market average55.19% above the market average55.19% above the market average55.19% above the market average55.19% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Angle Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

Angle Key Personnel

CEO Andrew D Newland
Finance Director Ian F Griffiths
Chair Jan Groen

Top of Page